Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

BACKGROUND: DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity. METHODS: Healthy participants aged 18–55...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, James S, Lotharius, Julie, Rückle, Thomas, Chalon, Stephan, Phillips, Margaret A, Elliott, Suzanne, Sekuloski, Silvana, Griffin, Paul, Ng, Caroline L, Fidock, David A, Marquart, Louise, Williams, Noelle S, Gobeau, Nathalie, Bebrevska, Lidiya, Rosario, Maria, Marsh, Kennan, Möhrle, Jörg J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446412/
https://www.ncbi.nlm.nih.gov/pubmed/28363636
http://dx.doi.org/10.1016/S1473-3099(17)30171-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446412/
https://www.ncbi.nlm.nih.gov/pubmed/28363636
http://dx.doi.org/10.1016/S1473-3099(17)30171-8

Ejemplares similares